An observational study in Parotid Gland Infection and Fever, sponsored by Jiangsu Province Centers for Disease Control and Prevention. Completed at 6 sites in China. Open to participants aged 3 Years to 7 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.
Sponsored by Jiangsu Province Centers for Disease Control and Prevention · Observational
This study was aimed to conduct a 3-year perspective study to observe the immunological effect of one-dose mumps-containing vaccine, monitor the incidence of mumps in vaccinated population aged 3-7 years，and provide basis for adjusting MMR immunization strategy in Jiangsu province, China.
in 3-7 years old children with high risk of mumps, epidemiological investigation of the serum IgG antibody level were conducted, and then a prospective observational cohort was established in the population with a history of mumps vaccination, and the incidence of mumps in each antibody level group will be observed, the relationship between different antibody levels and the incidence after mumps vaccinated were analyzed, to explore attenuation of mumps IgG antibody levels in the body,S79 vaccine strain against F genotype mumps' antigenic cross-reactivity and the protective effect of antibodies.
438 studies on the registry are indexed under Fever; 55 are open to participants now.
This study's enrollment of 7,901 is above the median of 408 across 140 observational studies indexed under Fever.
Browse Fever studies →Jiangsu Province Centers for Disease Control and Prevention is the lead sponsor of 77 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
children aged 3-7 years who received as least one dose mumps-containing vaccine
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
low geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
high geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
to describe the sero-prevalence in specific age groups following an active surveillance of vaccinated subjects in each year
Time frame: 3 years
to describe wane immunity of IgG antibody to mumps virus in specific age groups following an active surveillance of vaccinated subjects in each year
Time frame: 3 years
To characterize the incidence of mumps in specific age groups following an active surveillance of vaccinated subjects in each year
Time frame: 3 years
Plan to share: No
Ran from Oct 2015 to primary completion in Feb 2017, 16 months.
Of 51 non-industry observational studies under Fever, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's 16 months is below that.
Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jiangsu Province Centers for Disease Control and Prevention